☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☐ | TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 |
Delaware
|
77-0557236
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
incorporation)
|
Identification No.)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
Non-accelerated filer ☐
(Do not check if a smaller reporting company)
|
Smaller reporting company ☒
|
Page
|
|||
3
|
|||
3
|
|||
3
|
|||
4
|
|||
5
|
|||
6
|
|||
19
|
|||
25
|
|||
27
|
|||
27
|
|||
28
|
September 30,
|
December 31,
|
|||||||
2015
|
2014
|
|||||||
(Note 1)
|
||||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
7,650
|
$
|
10,923
|
||||
Marketable securities
|
-
|
29,790
|
||||||
Restricted cash, short-term
|
7,802
|
-
|
||||||
Prepaid expenses and other current assets
|
600
|
1,532
|
||||||
Total current assets
|
16,052
|
42,245
|
||||||
Property and equipment, net
|
366
|
414
|
||||||
Restricted cash, long-term
|
242
|
193
|
||||||
Other assets
|
81
|
125
|
||||||
Total assets
|
$
|
16,741
|
$
|
42,977
|
||||
|
||||||||
Liabilities and stockholders’ equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
1,018
|
$
|
1,822
|
||||
Accrued compensation
|
982
|
1,400
|
||||||
Deferred rent, short-term
|
50
|
16
|
||||||
Accrued research and clinical liabilities
|
2,391
|
3,470
|
||||||
Notes payable, net of discount
|
7,172
|
10,928
|
||||||
Financing derivative
|
341
|
89
|
||||||
Other accrued liabilities
|
381
|
328
|
||||||
Total current liabilities
|
12,335
|
18,053
|
||||||
Deferred rent, long-term
|
268
|
311
|
||||||
Total liabilities
|
12,603
|
18,364
|
||||||
|
||||||||
Stockholders’ equity:
|
||||||||
Common stock, $0.001 par value: 85,000,000 shares and 85,000,000 shares
authorized at September 30, 2015 and December 31, 2014, respectively; 4,123,921 and 4,124,004 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively |
4
|
4
|
||||||
Additional paid-in capital
|
204,609
|
202,830
|
||||||
Accumulated other comprehensive loss
|
-
|
(8
|
)
|
|||||
Accumulated deficit
|
(200,475
|
)
|
(178,213
|
)
|
||||
Total stockholders’ equity
|
4,138
|
24,613
|
||||||
Total liabilities and stockholders’ equity
|
$
|
16,741
|
$
|
42,977
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2015
|
2014
|
2015
|
2014
|
|||||||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
$
|
3,845
|
$
|
5,085
|
$
|
13,082
|
$
|
19,496
|
||||||||
General and administrative
|
2,359
|
2,624
|
8,095
|
7,907
|
||||||||||||
Total operating expenses
|
6,204
|
7,709
|
21,177
|
27,403
|
||||||||||||
|
||||||||||||||||
Loss from operations
|
(6,204
|
)
|
(7,709
|
)
|
(21,177
|
)
|
(27,403
|
)
|
||||||||
|
||||||||||||||||
Other (expense) income:
|
||||||||||||||||
Interest expense
|
(223
|
)
|
(348
|
)
|
(755
|
)
|
(898
|
)
|
||||||||
Interest income
|
3
|
24
|
29
|
69
|
||||||||||||
Change in fair market value of financing derivative
|
(114
|
)
|
-
|
(252
|
)
|
-
|
||||||||||
Other expense, net
|
(62
|
)
|
(30
|
)
|
(107
|
)
|
(53
|
)
|
||||||||
Net loss
|
(6,600
|
)
|
(8,063
|
)
|
(22,262
|
)
|
(28,285
|
)
|
||||||||
Other comprehensive income:
|
||||||||||||||||
Net unrealized gains (losses) on marketable
securities
|
-
|
-
|
8
|
(2
|
)
|
|||||||||||
Comprehensive loss
|
$
|
(6,600
|
)
|
$
|
(8,063
|
)
|
$
|
(22,254
|
)
|
$
|
(28,287
|
)
|
||||
|
||||||||||||||||
Basic and diluted net loss per common share
|
$
|
(1.60
|
)
|
$
|
(1.96
|
)
|
$
|
(5.40
|
)
|
$
|
(6.86
|
)
|
||||
|
||||||||||||||||
Weighted average common shares outstanding used to
|
||||||||||||||||
calculate basic and diluted net loss per common share
|
4,124,026
|
4,122,700
|
4,124,096
|
4,122,051
|
Nine Months Ended September 30,
|
||||||||
2015
|
2014
|
|||||||
(unaudited)
|
||||||||
Operating activities:
|
||||||||
Net loss
|
$
|
(22,262
|
)
|
$
|
(28,285
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
144
|
254
|
||||||
Loss on disposal of property and equipment
|
39
|
-
|
||||||
Noncash interest expense
|
164
|
160
|
||||||
Financing derivative
|
252
|
-
|
||||||
Amortization of premium on marketable securities
|
130
|
377
|
||||||
Stock based compensation expense
|
913
|
1,484
|
||||||
Modification of stock options related to executive retirement
|
389
|
-
|
||||||
Modification of stock options related to restructuring activities
|
479
|
-
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Prepaid expenses and other assets
|
940
|
(6
|
)
|
|||||
Accounts payable
|
(804
|
)
|
(2,277
|
)
|
||||
Accrued compensation
|
(418
|
)
|
289
|
|||||
Accrued research and clinical liabilities
|
(1,079
|
)
|
(1,324
|
)
|
||||
Other liabilities
|
53
|
82
|
||||||
Deferred rent
|
(9
|
)
|
169
|
|||||
Net cash used in operating activities
|
(21,069
|
)
|
(29,077
|
)
|
||||
Investing activities:
|
||||||||
Purchase of marketable securities
|
(3,703
|
)
|
(49,902
|
)
|
||||
Proceeds from maturities of marketable securities
|
33,371
|
34,190
|
||||||
Purchases of property and equipment
|
(136
|
)
|
(317
|
)
|
||||
Proceeds from disposal of property and equipment
|
1
|
-
|
||||||
Changes in restricted cash
|
7
|
12
|
||||||
Net cash provided by (used in) investing activities
|
29,540
|
(16,017
|
)
|
|||||
Financing activities:
|
||||||||
Increase in restricted cash for notes payable
|
(8,291
|
)
|
-
|
|||||
Proceeds from issuances of notes payable
|
-
|
5,000
|
||||||
Proceeds from issuance of common stock
|
-
|
60
|
||||||
Principal payments under notes payable
|
(3,452
|
)
|
(2,916
|
)
|
||||
Settlement of fractional shares upon reverse stock split
|
(1
|
)
|
-
|
|||||
Net cash (used in) provided by financing activities
|
(11,744
|
)
|
2,144
|
|||||
Net decrease in cash and cash equivalents
|
(3,273
|
)
|
(42,950
|
)
|
||||
Cash and cash equivalents, beginning of period
|
10,923
|
54,220
|
||||||
Cash and cash equivalents, end of period
|
$
|
7,650
|
$
|
11,270
|
||||
Supplemental cash flow disclosure:
|
||||||||
Cash paid for interest
|
$
|
564
|
$
|
725
|
||||
Supplemental disclosure of non-cash financing activities:
|
||||||||
Principal payments under notes payable from restricted cash
|
$
|
432
|
$
|
-
|
As of September 30,
|
||||
|
2015
|
|
2014
|
|
Options to purchase common stock
|
|
527,120
|
|
336,102
|
Unvested restricted stock units to purchase common stock
|
3,750
|
—
|
||
ESPP contributions to purchase common stock
|
375
|
430
|
||
Warrants to purchase common stock
|
|
11,067
|
|
11,067
|
|
542,312
|
|
347,599
|
Gross
|
Gross
|
|||||||||||||||
Amortized
|
Unrealized
|
Unrealized
|
||||||||||||||
(in thousands)
|
Cost
|
Gains
|
Losses
|
Fair Value
|
||||||||||||
Money market funds
|
$
|
7,396
|
$
|
—
|
$
|
—
|
$
|
7,396
|
||||||||
Total investments
|
$
|
7,396
|
$
|
—
|
$ |
$
|
7,396
|
|||||||||
Reported as:
|
||||||||||||||||
Cash and cash equivalents
|
$
|
7,154
|
||||||||||||||
Restricted cash, long-term
|
242
|
|||||||||||||||
Total investments
|
$
|
7,396
|
Gross
|
Gross
|
|||||||||||||||
Amortized
|
Unrealized
|
Unrealized
|
||||||||||||||
(in thousands)
|
Cost
|
Gains
|
Losses
|
Fair Value
|
||||||||||||
Money market funds
|
$
|
9,663
|
$
|
—
|
$
|
—
|
$
|
9,663
|
||||||||
Federal agency securities
|
13,774
|
—
|
(4
|
)
|
13,770
|
|||||||||||
Commercial paper
|
1,499
|
1
|
—
|
1,500
|
||||||||||||
Corporate debt securities
|
14,525
|
—
|
(5
|
)
|
14,520
|
|||||||||||
Total investments
|
$
|
39,461
|
$
|
1
|
$
|
(9
|
)
|
$
|
39,453
|
|||||||
Reported as:
|
||||||||||||||||
Cash and cash equivalents
|
$
|
9,470
|
||||||||||||||
Marketable securities
|
29,790
|
|||||||||||||||
Restricted cash
|
193
|
|||||||||||||||
Total investments
|
$
|
39,453
|
Fair Value Measurements as of
|
||||||||||||||||
September 30, 2015
|
||||||||||||||||
(in thousands)
|
Level 1
|
Level 2
|
Level 3
|
Total
|
||||||||||||
Investments:
|
||||||||||||||||
Money market funds
|
$
|
7,396
|
$
|
—
|
$
|
—
|
$
|
7,396
|
||||||||
Total assets measured at fair value
|
$
|
7,396
|
$ |
$
|
—
|
$
|
7,396
|
|||||||||
Financing derivative
|
$
|
—
|
$
|
—
|
$
|
341
|
$
|
341
|
||||||||
Total liabilities measured at fair value
|
$
|
—
|
$
|
—
|
$
|
341
|
$
|
341
|
Fair Value Measurements as of
|
||||||||||||||||
December 31, 2014
|
||||||||||||||||
(in thousands)
|
Level 1
|
Level 2
|
Level 3
|
Total
|
||||||||||||
Investments:
|
||||||||||||||||
Money market funds
|
$
|
9,663
|
$
|
—
|
$
|
—
|
$
|
9,663
|
||||||||
Federal agency securities
|
—
|
13,770
|
—
|
13,770
|
||||||||||||
Commercial paper
|
—
|
1,500
|
—
|
1,500
|
||||||||||||
Corporate debt securities
|
—
|
14,520
|
—
|
14,520
|
||||||||||||
Total assets measured at fair value
|
$
|
9,663
|
$
|
29,790
|
$
|
—
|
$
|
39,453
|
||||||||
Financing derivative
|
$
|
—
|
$
|
—
|
$
|
89
|
$
|
89
|
||||||||
Total liabilities measured at fair value
|
$
|
—
|
$
|
—
|
$
|
89
|
$
|
89
|
Fair Value
Measurements of Level 3 Liabilities |
||||
(in thousands)
|
||||
Balance as of December 31, 2014
|
$
|
89
|
||
Loss on re-measurement of the financing derivative liability
|
3
|
|||
Balance as of March 31, 2015
|
92
|
|||
Loss on re-measurement of the financing derivative liability
|
135
|
|||
Balance as of June 30, 2015
|
227
|
|||
Loss on re-measurement of the financing derivative liability
|
114
|
|||
Balance as of September 30, 2015
|
$
|
341
|
Weighted
|
||||||||
Average
|
||||||||
Exercise
|
||||||||
Options
|
Price
|
|||||||
Outstanding at December 31, 2014
|
334,686
|
$
|
34.00
|
|||||
Granted
|
296,045
|
3.59
|
||||||
Exercised
|
—
|
—
|
||||||
Cancelled (forfeited)
|
(96,158
|
)
|
24.55
|
|||||
Cancelled (expired)
|
(7,453
|
)
|
18.22
|
|||||
Outstanding at September 30, 2015
|
527,120
|
$
|
18.84
|
Three Months
Ended |
Nine Months
Ended
|
|||||||
Exercise price
|
$
|
3.23
|
$
|
3.59
|
||||
Market value
|
$
|
3.23
|
$
|
3.59
|
||||
Risk-free rate
|
1.62
|
1.61
|
||||||
Expected term
|
5.30
|
5.81
|
||||||
Expected volatility
|
69
|
%
|
70
|
%
|
||||
Dividend yield
|
-
|
-
|
Three Months
|
Nine Months
|
|||||||||||||||
Ended September 30,
|
Ended September 30,
|
|||||||||||||||
(in thousands)
|
2015
|
2014
|
|
2015
|
2014
|
|||||||||||
General and administrative
|
$
|
137
|
$
|
282
|
$
|
466
|
$
|
755
|
||||||||
Research and development
|
134
|
184
|
447
|
729
|
||||||||||||
$
|
271
|
$
|
466
|
$
|
913
|
$
|
1,484
|
(in thousands)
|
Contract
termination costs - R&D |
Salaries and
benefits - R&D
|
Salaries and
benefits - G&A
|
Total
|
||||||||||||
Balance as of December 31, 2014
|
$
|
1,185
|
$
|
—
|
$
|
—
|
$
|
1,185
|
||||||||
Accrued
|
—
|
522
|
82
|
604
|
||||||||||||
Paid
|
(479
|
)
|
(257
|
)
|
—
|
(736
|
)
|
|||||||||
Balance as of March 31, 2015
|
$
|
706
|
$
|
265
|
$
|
82
|
$
|
1,053
|
||||||||
Accrued
|
—
|
57
|
122
|
179
|
||||||||||||
Paid
|
(135
|
)
|
(142
|
)
|
—
|
(277
|
)
|
|||||||||
Balance as of June 30, 2015
|
$
|
571
|
$
|
180
|
$
|
204
|
$
|
955
|
||||||||
Accrued
|
—
|
—
|
—
|
—
|
||||||||||||
Adjustments
|
(78
|
)
|
—
|
—
|
(78
|
)
|
||||||||||
Paid
|
(493
|
)
|
(148
|
)
|
(136
|
)
|
(777
|
)
|
||||||||
Balance as of September 30, 2015
|
$
|
-
|
$
|
32
|
$
|
68
|
$
|
100
|
· | $3,000,000 (the “Initial Payment”) payable as soon as practicable but in no event later than the Company emerging from its Chapter 11 bankruptcy pursuant to a plan of reorganization (the “Bankruptcy Exit”); |
· | a five-year warrant from the date of the Bankruptcy Exit to purchase up to 200,000 shares of common stock at a per share price of $2.25, exercisable for 25% of the shares immediately and exercisable for the remaining shares upon reaching certain milestones related to regulatory approval of the Compound; and |
· | certain additional payments to be further specified in the definitive agreements. |
· | purchasing any stock or assets of the Company; |
· | participating in any proposal for any merger, tender offer or other business combination, or similar extraordinary transaction involving the Company or any of its subsidiaries; |
· | seeking to control or influence the management, the Company’s Board or the policies of the Company; or |
· | submitting any proposal to be considered by the stockholders of the Company. |
· | expenses incurred under agreements with contract research organizations, investigative sites, and consultants that conduct our clinical trials and a substantial portion of our preclinical activities; |
· | the cost of acquiring and manufacturing clinical trial and other materials; and |
· | other costs associated with development activities, including additional studies. |
For the
|
For the
|
For the Period from
|
||||||||||||||||||
Three Months Ended
|
Nine Months Ended
|
January 1, 2008 to
|
||||||||||||||||||
September 30,
|
September 30,
|
September 30, 2015
|
||||||||||||||||||
(in thousands)
|
2015
|
2014
|
2015
|
2014
|
||||||||||||||||
External Costs:
|
||||||||||||||||||||
KB001-A
|
47
|
1,640
|
1,262
|
4,663
|
33,842
|
|||||||||||||||
Lenzilumab
|
68
|
290
|
318
|
3,494
|
40,481
|
|||||||||||||||
Ifabotuzumab
|
$
|
2,131
|
$
|
1,063
|
$
|
5,611
|
$
|
4,522
|
$
|
37,251
|
||||||||||
Internal Costs
|
1,599
|
2,092
|
5,891
|
6,817
|
69,967
|
|||||||||||||||
Total research and development
|
$
|
3,845
|
$
|
5,085
|
$
|
13,082
|
$
|
19,496
|
$
|
181,541
|
Three Months Ended September 30,
|
Increase/ (Decrease)
|
|||||||||||||||
(in thousands)
|
2015
|
2014
|
in thousands
|
%
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
$
|
3,845
|
$
|
5,085
|
$
|
(1,240
|
)
|
(24
|
)
|
|||||||
General and administrative
|
2,359
|
2,624
|
(265
|
)
|
(10
|
)
|
||||||||||
Loss from operations
|
(6,204
|
)
|
(7,709
|
)
|
(1,505
|
)
|
(20
|
)
|
||||||||
Interest expense
|
(223
|
)
|
(348
|
)
|
(125
|
)
|
(36
|
)
|
||||||||
Interest income
|
3
|
24
|
(21
|
)
|
(88
|
)
|
||||||||||
Change in fair market value of financing derivative
|
(114
|
)
|
-
|
114
|
100
|
|||||||||||
Other (expense) income, net
|
(62
|
)
|
(30
|
)
|
32
|
107
|
||||||||||
Net loss
|
$
|
(6,600
|
)
|
$
|
(8,063
|
)
|
$
|
(1,463
|
)
|
(18
|
)
|
Nine Months Ended September 30,
|
Increase/ (Decrease)
|
|||||||||||||||
(in thousands)
|
2015
|
2014
|
in thousands
|
%
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
$
|
13,082
|
$
|
19,496
|
$
|
(6,414
|
)
|
(33
|
)
|
|||||||
General and administrative
|
8,095
|
7,907
|
188
|
2
|
||||||||||||
Loss from operations
|
(21,177
|
)
|
(27,403
|
)
|
(6,226
|
)
|
(23
|
)
|
||||||||
Interest expense
|
(755
|
)
|
(898
|
)
|
(143
|
)
|
(16
|
)
|
||||||||
Interest income
|
29
|
69
|
(40
|
)
|
(58
|
)
|
||||||||||
Change in fair market value of financing derivative
|
(252
|
)
|
-
|
252
|
100
|
|||||||||||
Other (expense) income, net
|
(107
|
)
|
(53
|
)
|
54
|
102
|
||||||||||
Net loss
|
$
|
(22,262
|
)
|
$
|
(28,285
|
)
|
$
|
(6,023
|
)
|
(21
|
)
|
Nine Months Ended
|
||||||||
September 30,
|
||||||||
(in thousands)
|
2015
|
2014
|
||||||
Net cash used in operating activities
|
$
|
(21,069
|
)
|
$
|
(29,077
|
)
|
||
Net cash provided by (used in) investing activities
|
29,540
|
(16,017
|
)
|
|||||
Net cash (used in) provided by financing activities
|
(11,744
|
)
|
2,144
|
|||||
Net decrease in cash and cash equivalents
|
$
|
(3,273
|
)
|
$
|
(42,950
|
)
|
· | the type, number, timing, progress, costs, and results of the product candidate development programs that we are pursuing or may choose to pursue in the future; |
· | the scope, progress, expansion, costs, and results of our pre-clinical and clinical trials; |
· | the timing of and costs involved in obtaining regulatory approvals; |
· | our ability to establish and maintain development partnering arrangements and any associated funding; |
· | the emergence of competing products or technologies and other adverse market developments; |
· | the costs of maintaining, expanding, and protecting our intellectual property portfolio, including potential litigation costs and liabilities; |
· | the resources we devote to marketing, and, if approved, commercializing our product candidates; |
· | the scope, progress, expansion and costs of manufacturing our product candidates; and |
· | the costs associated with being a public company. |
KALOBIOS PHARMACEUTICALS, INC.
|
|||
Date: September 1, 2016
|
By:
|
/s/ Cameron Durrant
|
|
Cameron Durrant
|
|||
Chief Executive Officer
|
|||
(Principal Executive Officer)
|
|||
Date: September 1, 2016
|
By:
|
/s/ Dean Witter
|
|
Dean Witter, III
|
|||
Interim Chief Financial Officer
|
|||
(Principal Financial and Accounting Officer)
|
Exhibit No.
|
Description
|
||
3.1
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on July 13, 2015 (File No. 001-35798)).
|
||
10.1*
|
2012 Equity Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 10, 2015 (File No. 001-35798)).
|
||
10.2
|
Amendment No. Two to Loan and Security Agreement, by and between KaloBios Pharmaceuticals, Inc. and MidCap Financial SBIC, LP, dated as of August 7, 2015.
|
||
31.1
|
Certification of Chief Executive Officer of the Registrant, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
31.2
|
Certification of Interim Chief Financial Officer of the Registrant, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
32.1†
|
Certification by the Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 36 of Title 18 of the United States Code (18 U.S.C. §1350).
|
||
32.2†
|
Certification by the Interim Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 36 of Title 18 of the United States Code (18 U.S.C. §1350).
|
||
101.INS
|
XBRL Instance Document
|
||
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
||
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
||
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
||
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
||
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
* | Indicates management contract or compensatory plan. |
† | The Certifications attached as Exhibits 32.1 and 32.2 that accompanies this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of KaloBios Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. |
BORROWER:
|
KALOBIOS PHARMACEUTICALS, INC.
|
||
By:
|
/s/ Herb Cross
|
||
Name:
|
Herb Cross
|
||
Title:
|
CFO and Interim CEO
|
MIDCAP FINANCIAL TRUST,
as Agent for Lenders
By: Apollo Capital Management, L.P., its
investment manager
By: Apollo Capital Management GP, LLC, its
general partner
|
|||
By:
|
/s/ Maurice Amsellem
|
||
Name:
|
Maurice Amsellem
|
||
Title:
|
Authorized Signatory
|
MIDCAP FUNDING XIII TRUST
By: Apollo Capital Management, L.P., its
investment manager
By: Apollo Capital Management GP, LLC, its
general partner
|
|||
By:
|
/s/ Maurice Amsellem
|
||
Name:
|
Maurice Amsellem
|
||
Title:
|
Authorized Signatory
|
FLEXPOINT MCLS SPV LLC
|
|||
By:
|
/s/ Daniel Edelman
|
||
Name:
|
Daniel Edelman
|
||
Title:
|
Vice President
|
/s/ Cameron Durrant
|
||
Cameron Durrant,
|
||
Chief Executive Officer
|
||
(Principal Executive Officer)
|
/s/ Dean Witter
|
||
Dean Witter, III
|
||
Interim Chief Financial Officer
|
||
(Principal Financial and Accounting Officer)
|
By:
|
/s/ Cameron Durrant
|
|||
Name:
|
Cameron Durrant
|
|||
Title:
|
Chief Executive Officer
|
|||
(Principal Executive Officer)
|
||||
Date:
|
September 1, 2016
|
By:
|
/s/ Dean Witter, III
|
||
Name:
|
Dean Witter, III
|
||
Title:
|
Chief Financial Officer
|
||
(Principal Financial and Accounting Officer)
|
|||
Date:
|
September 1, 2016
|
Document and Entity Information - shares |
9 Months Ended | |
---|---|---|
Sep. 30, 2015 |
Aug. 30, 2016 |
|
Document and Entity Information | ||
Entity Registrant Name | KALOBIOS PHARMACEUTICALS INC | |
Entity Central Index Key | 0001293310 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2015 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | No | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 14,897,993 | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q3 |
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares |
Sep. 30, 2015 |
Dec. 31, 2014 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 85,000,000 | 85,000,000 |
Common stock, shares issued | 4,123,921 | 4,124,004 |
Common stock, shares outstanding | 4,123,921 | 4,124,004 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
|
Operating expenses: | ||||
Research and development | $ 3,845 | $ 5,085 | $ 13,082 | $ 19,496 |
General and administrative | 2,359 | 2,624 | 8,095 | 7,907 |
Total operating expenses | 6,204 | 7,709 | 21,177 | 27,403 |
Loss from operations | (6,204) | (7,709) | (21,177) | (27,403) |
Other (expense) income: | ||||
Interest expense | (223) | (348) | (755) | (898) |
Interest income | 3 | 24 | 29 | 69 |
Change in fair market value of financing derivative | (114) | (252) | ||
Other expense, net | (62) | (30) | (107) | (53) |
Net loss | (6,600) | (8,063) | (22,262) | (28,285) |
Other comprehensive income: | ||||
Net unrealized gains (losses) on marketable securities | 8 | (2) | ||
Comprehensive loss | $ (6,600) | $ (8,063) | $ (22,254) | $ (28,287) |
Basic and diluted net loss per common share | $ (1.60) | $ (1.96) | $ (5.40) | $ (6.86) |
Weighted average common shares outstanding used to calculate basic and diluted net loss per common share | 4,124,026 | 4,122,700 | 4,124,096 | 4,122,051 |
Nature of Operations |
9 Months Ended |
---|---|
Sep. 30, 2015 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Operations | 1. Nature of Operations
Description of the Business
KaloBios
Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company focused on developing medicines for
patients with neglected and rare diseases, with an ancillary focus on pediatric conditions, and on executing its Responsible
Pricing Model in the commercialization of the Company’s product candidates that may be approved. The Company’s
lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term
heart, intestinal and neurological problems. As more fully described in note 10, the Company acquired certain worldwide
rights to benznidazole on June 30, 2016. The Company is developing one of its proprietary monoclonal antibodies,
lenzilumab (formerly known as KB003), for the treatment of chronic myelomonocytic leukemia and potentially for the treatment
of juvenile myelomonocytic leukemia, both of which are rare hematologic cancers with high unmet medical need. The Company is
exploring development of another of its proprietary monoclonal antibodies, ifabotuzumab (formerly known as KB004), for the
treatment of certain rare solid and hematologic cancers. With a focus on neglected, rare, and orphan diseases, the Company
believes that it has the opportunity to benefit from various regulatory incentives, such as orphan drug exclusivity,
breakthrough therapy designation, fast track designation, accelerated approval, priority review and priority review vouchers
(“PRV”), where available, that provide for certain periods of exclusivity, expedited review and/or other
benefits.
The Company was incorporated on March 15, 2000 in California and reincorporated as a Delaware corporation in September 2001. All of the Company’s assets are located in California.
Liquidity and Going Concern
The Company has historically incurred significant losses and had an accumulated deficit of $200.5 million as of September 30, 2015. The Company has financed its operations primarily through the sale of equity securities, grants and the payments received under its agreements with Novartis Pharma AG and Sanofi Pasteur S.A. (“Sanofi”). The Company completed its initial public offering in February 2013. To date, none of the Company’s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses to continue for the foreseeable future. As a result, the Company will continue to require additional capital through equity offerings, debt financing and/or payments under new or existing licensing or collaboration agreements. If sufficient funds are not available on acceptable terms when needed, the Company could be required to significantly reduce its operating expenses and delay, reduce the scope of, or eliminate one or more of its development programs. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis when needed, could materially harm its business, financial condition and results of operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
The Condensed Consolidated Financial Statements for the quarterly period ended September 30, 2015 were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. The ability of the Company to meet its total liabilities of $12.6 million at September 30, 2015, and to continue as a going concern is dependent upon the availability of future funding. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Basis of Presentation
The accompanying interim unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and on a basis consistent with the annual consolidated financial statements and include all adjustments necessary for the presentation of the Company’s condensed consolidated financial position, results of operations and cash flows for the periods presented. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. These financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The December 31, 2014 Condensed Consolidated Balance Sheet was derived from the audited financial statements but does not include all disclosures required by GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2015, or for any other future annual or interim period. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the 2014 Annual Report.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in determining the valuation of the financing derivative, the fair value-based measurement of stock-based compensation, accruals and warrant valuations. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Condensed Consolidated Financial Statements. |
Summary of Significant Accounting Policies |
9 Months Ended |
---|---|
Sep. 30, 2015 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies
There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2014 Annual Report. |
Potentially Dilutive Securities |
9 Months Ended | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | ||||||||||||||||||||||||||||||||||||
Potentially Dilutive Securities | ||||||||||||||||||||||||||||||||||||
Potentially Dilutive Securities | 3. Potentially Dilutive Securities
The Company’s potential dilutive securities, which include unvested stock options and warrants, have been excluded from the computation of diluted net loss per share as the effect of including those securities would be to reduce the net loss per share and be antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented.
The following outstanding potentially dilutive securities have been excluded from the computations of diluted net loss per common share:
|
Investments |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments, Debt and Equity Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments | 4. Investments
At September 30, 2015, the amortized cost and fair value of investments, with gross unrealized gains and losses, were as follows:
At December 31, 2014, the amortized cost and fair value of investments, with gross unrealized gains and losses, were as follows:
The Company realized a net loss from the sale of marketable securities of $8,000 for the three and nine months ended September 30, 2015. There were no realized gains or losses from the sale of marketable securities for the three and nine months ended September 30, 2014. |
Fair Value of Financial Instruments |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Financial Instruments | 5. Fair Value of Financial Instruments
Cash, accounts payable and accrued liabilities are carried at cost, which approximates fair value given their short-term nature. Marketable securities and cash equivalents are carried at fair value.
The fair value of financial instruments reflects the amounts that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable, and the third is considered unobservable, as follows:
Level 1 — Quoted prices in active markets for identical assets or liabilities.
Level 2 — Inputs other than those included in Level 1 that are directly or indirectly observable, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The Company measures the fair value of financial assets and liabilities using the highest level of inputs that are reasonably available as of the measurement date. The following tables summarize the fair value of financial assets and liabilities (marketable securities and the financing derivative) that are measured at fair value and the classification by level of input within the fair value hierarchy:
The Company’s Level 2 investments include U.S. government-backed securities, commercial paper and corporate debt securities that are valued based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. The Company did not have any Level 2 investments as of September 30, 2015.
In 2014, the Company recorded a financing derivative liability resulting from an embedded derivative related to the prepayment feature of its loan and security agreement with MidCap Financial SBIC LP, which was entered into by the Company in September 2012 and subsequently amended (the “Loan and Security Agreement”). At September 30, 2015, the Company re-measured the financing derivative liability as $341,000, resulting in a loss of $114,000 and $252,000 for the three and nine month periods ended September 30, 2015. The loss is included in Change in fair value of financing derivative in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss. The fair value of this derivative was determined using Level 3 inputs, or significant unobservable inputs. The value of the financing derivative was determined by comparing the difference between the fair value of the notes payable with and without the financing derivative by calculating the respective present values from future cash flows using a 14% discount rate, adjusted for the probability of the occurrence of an event of default under the Loan and Security Agreement. The 14% discount rate assumption was based on an effective borrowing rate under the current circumstances considering the quoted borrowing rate for the Company and the imputed fair value of any additional financial instruments that may be required to be extended to the lender in order to obtain such debt financing. The probability of the occurrence of an event of default under the Loan and Security Agreement was based on management’s judgment. Refer to Note 6 for additional details regarding the Loan and Security Agreement.
The following table presents changes in financial instruments measured at fair value using Level 3 inputs:
The estimated fair value of the notes payable as of September 30, 2015, based on current market rates for similar borrowings, as measured using Level 3 inputs, approximates the carrying amount as presented on the Condensed Consolidated Balance Sheets. |
Notes Payable |
9 Months Ended |
---|---|
Sep. 30, 2015 | |
Debt Disclosure [Abstract] | |
Notes Payable | 6. Notes Payable
Loan and Security Agreement
In August 2015, the Company entered into Amendment No. 2 to the Loan and Security Agreement, whereby the Company agreed to maintain, in a separate account with a financial institution (held in the Company’s name), an amount equal to the aggregate of the remaining future principal, interest and exit fee due under the Loan and Security Agreement, equating to $8.3 million as of the date of Amendment No. 2. Under the terms of the Loan and Security Agreement, as amended, MidCap Financial was permitted to draw payments from this account as they become due, and upon such draws, there would be a corresponding reduction in the amount owed to MidCap Financial by the Company. MidCap Financial had exclusive control to withdraw funds from that account at any time. The account was to be maintained either until the debt has been repaid in full, or until MidCap Financial determined that the Company has satisfied certain capital requirements related to the Company’s future operating plans. As of September 30, 2015, the Company had $7.8 million in this restricted account.
In November 2015, the Company elected to exercise its prepayment right to repay the loan in full and paid MidCap Financial $6.6 million in full settlement of the remaining outstanding principal balance, accrued interest, the exit fee and a reduced prepayment fee of 1%. The prepayment resulted in a gain on extinguishment of debt of $61,000 in the fourth quarter of 2015.
As of September 30, 2015, the Company classified the loan as a current liability. Refer to Note 10 for additional details regarding the repayment of the Loan and Security Agreement. |
Commitments and Contingencies |
9 Months Ended |
---|---|
Sep. 30, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 7. Commitments and Contingencies
Contractual Obligations and Commitments
As of September 30, 2015, there were no material changes to the Company’s contractual obligations from those set forth in the 2014 Annual Report.
Guarantees and Indemnifications
The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for or expenses related to indemnification issues for any period presented. |
Stockholders' Equity |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity | 8. Stockholders’ Equity
2012 Equity Incentive Plan
Under the Company’s 2012 Equity Incentive Plan, the Company may grant shares, stock units, stock appreciation rights, performance cash awards and/or options to employees, directors, consultants, and other service providers. For options, the per share exercise price may not be less than the fair market value of a Company common share on the date of grant. Awards generally vest and become exercisable over four years and expire 10 years from the date of grant.
A summary of stock option activity for the nine months ended September 30, 2015 under all of the Company’s options plans is as follows:
The weighted average fair value of options granted during the three months and nine months ended September 30, 2015 was $1.90 and $2.23 per share, respectively.
The Company valued the options granted using the Black-Scholes options pricing model and the following weighted-average assumption terms for the three months and nine months ended September 30, 2015:
In addition, 3,750 restricted stock units were issued as of September 30, 2015.
2012 Employee Stock Purchase Plan
The Employee
Stock Purchase Plan (the “ESPP”) provided eligible employees with the opportunity to acquire an ownership
interest in the Company through periodic payroll deductions, based on a six-month look-back period, at a price equal to the
lesser of 85% of the fair market value of the ordinary shares at either the beginning of the offering period, or the fair
market value on the purchase date. The ESPP was structured as a qualified employee stock purchase plan under Section 423 and
a qualified pension, profit sharing or stock bonus plan under Section 401(a) of the Internal Revenue Code of 1986 and was not
subject to the provisions of the Employee Retirement Income Security Act of 1974. There were 21,058 shares initially
authorized for issuance under the plan, and the first offering period commenced on June 1, 2014 and ended on October 31,
2014. The second offering period commenced on November 1, 2014 and ended on April 30, 2015. There were 583 and 375 shares
issued under the plan on October 31, 2014 and April 30, 2015, respectively. Under the terms of the ESPP, offerings subsequent
to the second offering were to commence on May 1 and November 1 and end on April 30 and October 31 each year. As of
September 30, 2015, there were 20,100 shares available for grant under the ESPP. On May 3, 2016, the ESPP was
terminated.
Stock-Based Compensation
The Company recorded stock-based compensation expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss as follows:
During the nine months ended September 30, 2015, the Company recorded charges of $389,000 and $479,000 relating to the fair value of stock options that were modified due to executive retirement and restructuring activities, and classified $484,000 and $384,000, as general and administrative expenses and research and development expenses, respectively.
At September 30, 2015, the Company had $1.4 million of total unrecognized stock-based compensation expense, net of estimated forfeitures, related to outstanding stock options that will be recognized over a weighted-average period of 1.4 years.
Reverse Stock Split
On July 13, 2015, the Company effected a one-for-eight reverse split of its outstanding common stock pursuant to an amendment to the Company’s certificate of incorporation. As a result of the reverse stock split, each eight shares of the Company’s common stock were combined into one share of common stock. The reverse stock split was effective with respect to stockholders of record at the close of business on July 13, 2015, and trading of the Company’s common stock on the Nasdaq Global Market began on a split-adjusted basis on July 14, 2015. Holders of common stock who would have otherwise received fractional shares of the Company’s common stock pursuant to the reverse split received cash in lieu of the fractional share. The reverse split reduced the total number of shares of the Company’s common stock outstanding from approximately 33.0 million shares to approximately 4.1 million shares. In addition, the number of shares of common stock subject to outstanding options, restricted stock units and warrants issued by the Company and the number of shares reserved for future issuance under the Company’s stock plans were reduced by a factor of eight to proportionately reflect the reverse split, and per share exercise prices were increased by a factor of eight. The reverse split was accounted for retroactively and is reflected in the Company’s common stock, warrant, stock option and restricted stock activity as of and for the three and nine months ended September 30, 2015 and 2014. Unless stated otherwise, all share data in the financial statements and accompanying notes have been adjusted, as appropriate, to reflect the reverse split. The par value per share and number of authorized shares were not adjusted as a result of the reverse stock split. |
Restructuring Charges |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Charges | 9. Restructuring Charges
Restructuring charges incurred during the nine months ended September 30, 2015 primarily consist of severance and other post-termination benefit costs resulting from the cost reduction program implemented by the Company in January 2015. These activities primarily consisted of a 20% reduction of the Company’s workforce. A summary of the activity is presented below:
As disclosed in Note 8, during the nine months ended September 30, 2015, the Company recorded stock based compensation expense of $479,000 related to the fair value of stock options of former employees which were modified such that they did not expire upon termination. The Company classified $95,000 and $384,000 as general and administrative expenses and research and development expenses, respectively.
As of December 31, 2014, the Company accrued certain contract termination costs of $1.2 million relating to manufacturing activity that no longer had identifiable future benefit to the Company. During the second quarter ended June 30, 2015, accrued liabilities were reduced by $312,000 related to research-related manufacturing expenses incorrectly recorded in 2014. The Company analyzed and assessed the effect of this adjustment on previously reported annual and interim periods in 2014 as well as the impact of the benefit from the reversal of these expenses to the results of operations for the nine months ended September 30, 2015. Following this analysis and taking into account both quantitative and qualitative factors, the Company believes that the uncorrected out-of-period costs are not material to the respective periods in which the errors occurred. |
Subsequent Events |
9 Months Ended | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | ||||||||||||||||||||||
Subsequent Events [Abstract] | ||||||||||||||||||||||
Subsequent Events | 10. Subsequent Events
Restructuring Expenses
In November 2015, the Company issued a press release announcing a board-approved restructuring plan to reduce costs and extend the cash runway in order to allow the Company to evaluate strategic alternatives for the products and the Company. As part of the restructuring plan, the Company elected to exercise its right to prepay the Loan and Security Agreement and paid MidCap Financial $6.6 million in full settlement of the remaining outstanding principal balance, accrued interest, the exit fee and a reduced prepayment fee of 1%. In addition, the Company undertook a reduction in force that eliminated the positions of 17 employees, or more than 60% of the Company’s workforce, which resulted in restructuring charges of approximately $1.4 million to be recorded in the fourth quarter of 2015.
Change of Control, Severance Costs and Private Placement
In November 2015, the Company underwent a change of control, when an investor group acquired an aggregate of 2,885,000 shares of the Common Stock in open market transactions, or approximately 70.0% of the then outstanding shares of the Common Stock.
In connection with that change in control, on November 19, 2015, certain former board members and executives left the Company. The severance costs associated with the departure of the executives amounted to approximately $1.6 million. The Company classified $1.2 million and $0.4 million of the severance costs as general and administrative expenses and research and development expenses, respectively, to be recorded in the fourth quarter of 2015.
On December 3, 2015, the Company entered into a Securities Purchase Agreement with certain investors (the “Purchasers”) relating to a private placement of up to an aggregate 511,596 shares of common stock at a purchase price of $29.32 per share, or up to $15 million (the “Private Placement”). On December 15, 2015, the Securities Purchase Agreement was amended, resetting the share price for all Purchasers other than those Purchasers who were directors, officers, employees or consultants of the Company to $24.855. Upon closing of the Private Placement, the Company issued to the Purchasers 326,698 shares of common stock for an aggregate purchase price of $8.2 million.
On December 4, 2015, the Company issued a warrant to purchase up to an aggregate of 125,000 shares of common stock at $29.32 per share exercisable for a period of five years. The warrant was issued in relation to a proposed November 18, 2015 financing the Company elected not to pursue.
On December 3, 2015, the Company entered into a Services Agreement (the “Services Agreement”) with Turing Pharmaceuticals LLC (“Turing”), a life sciences company. The Company’s then Chairman and Chief Executive Officer, Martin Shkreli, was also the chief executive officer and a member of the board of directors of Turing. Pursuant to the Services Agreement, Turing was to provide certain employees to the Company, to utilize on a part-time basis, including Christopher Thorn, who was appointed as the Company’s interim chief financial officer on December 3, 2015. The Services Agreement provided that Turing would charge the Company for Mr. Thorn’s services at an hourly rate of $151.92 per hour, and Mr. Thorn would remain employed and compensated by Turing during the term of the Services Agreement. No amounts have been, or will be, paid by the Company to Turing, and Mr. Thorn resigned on December 21, 2015.
Bankruptcy Filing and Delisting of Common Stock
On December 29, 2015, the Company filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code (the “Bankruptcy Code”). The filing was made in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) (Case No. 15-12628). As described below, the Company emerged from bankruptcy on June 30, 2016 (the “Effective Date”).
As a result of delisting procedures implemented by The NASDAQ Stock Market in December 2015, on January 13, 2016, the Company’s common stock was suspended from the Nasdaq Global Market and began trading on the over-the-counter market. On January 26, 2016, NASDAQ filed a Form 25 with the Securities and Exchange Commission to complete the delisting of the common stock, and the delisting was effective on February 5, 2016.
Bankruptcy Related Financing Arrangements
On April 1, 2016, the Company entered into a Debtor in Possession Credit and Security Agreement (the “Credit Agreement”) with Black Horse Capital Master Fund Ltd., as administrative agent and lender (“BHCMF” or “Agent”), Black Horse Capital LP, as a lender (“BHC”), Cheval Holdings, Ltd., as a lender (“Cheval”) and Nomis Bay LTD, as a lender (“Nomis” and, together with BHCMF, BHC and Cheval, the “Lenders”). The Credit Agreement provided for a debtor-in-possession credit facility in the original principal amount of $3,000,000 (the “Term Loan”). The Credit Agreement provided that the Term Loan will be made by the Lenders at an original discount equal to $191,000 (the “Upfront Fee”) and required the payment by the Company to the Lenders of a commitment fee equal to $150,000 (the “Commitment Fee”). In accordance with the terms of the Credit Agreement, the Company used the proceeds of the Term Loan for working capital, bankruptcy-related costs, costs related to the Company’s plan of reorganization, the payment of certain fees and expenses owed to the Agent and the Lenders in connection with the Credit Agreement and other costs incurred in the ordinary course of business.
Pursuant to the terms of the Credit Agreement, the Term Loan bore interest at a rate per annum equal to 12.00%.
In accordance with the bidding procedures order entered by the Bankruptcy Court, the Term Loan and the SPA (defined below) were together subject to competing, higher and better offers.
The Company’s obligations under the Credit Agreement were secured pursuant to an Intellectual Property Security Agreement.
In connection with the Credit Agreement, the Company executed in favor of Agent an Intellectual Property Security Agreement, dated as of April 1, 2016 (the “IP Security Agreement”). Under the terms of the IP Security Agreement, the Company pledged to Agent for the ratable benefit of the Lenders, as collateral for its obligations under the Credit Agreement, all of its intellectual property.
The Credit Agreement provided that the outstanding principal balance of the Term Loan, plus accrued and unpaid interest, plus the Upfront Fee, plus the Commitment Fee and all other non-contingent obligations would mature on the earlier of an event of default under the Credit Agreement or the effective date of the Company’s plan of reorganization. The Maturity Date was deemed to occur simultaneously with the Effective Date and, accordingly, on June 30, 2016, 2,350,480 shares of common stock were issued to the Lenders in repayment of the Company’s debt obligations under the Credit Agreement, including 201,436 shares to BHC, 470,096 shares to BHCMF, 503,708 shares to Cheval, 940,192 shares to Nomis and 235,048 shares to Cortleigh Limited (“Cortleigh”). Pursuant to the terms of the Credit Agreement, the Company also paid $405,145 to BHC in payment of its fees and expenses and $283,132 to Nomis in payment of its fees and expenses.
On April 1, 2016, the Company also entered into a Securities Purchase Agreement (the “SPA”) with the Lenders. The SPA provides for the sale to the Lenders on the closing date of an aggregate of 5,885,000 shares of common stock, subject to adjustment as provided in the SPA, in respect of exit financing in the amount of $11,000,000 (the “Exit Financing”) plus an exit financing commitment fee of $770,000 payable by the Company to the Lenders, plus payment to the Lenders of their fees and expenses incurred in connection with the Exit Financing and the SPA. Nomis subsequently assigned twenty percent (20%) of its interest in the shares of common stock to be purchased by Nomis under the SPA and the Credit Agreement to Cortleigh (collectively with the Lenders, the “Purchasers”).
The consummation of the transactions contemplated by the SPA were contingent on, among other things, the funding of the Term Loan, the approval of the Bankruptcy Court of the Company’s plan of reorganization, and the simultaneous closing of the Company’s transaction with Savant, as described below. In addition, the closing of the transactions under the SPA were contingent upon the board of directors of the Company, upon the effectiveness of the confirmed plan of reorganization, consisting of (i) one director to be designated by Nomis; (ii) one director to be jointly designated by BHC, BHCF, and Cheval; (iii) the Chief Executive Officer of the Company to be designated jointly and unanimously by the Lenders; and (iv) two independent directors to be designated jointly and unanimously by the Lenders.
The issuance of the shares contemplated by the SPA was consummated on the Effective Date, and the Company issued to the Purchasers an aggregate of 7,147,035 shares of common stock for an aggregate purchase price of $11,000,000, including 612,501 shares to BHC, 1,429,407 shares to BHCMF, 1,531,610 shares to Cheval, 2,858,814 shares to Nomis and 714,703 shares to Cortleigh. Pursuant to the terms of the SPA, the Company paid $427,383 to BHC in payment of its fees and expenses and $240,773 to Nomis in payment of its fees and expenses.
Emergence from Bankruptcy
On May 9, 2016, the Company filed with the Bankruptcy Court a Second Amended Plan of Reorganization (the “Plan”) and related amended disclosure statement pursuant to Chapter 11 of the Bankruptcy Code. On June 16, 2016, the Bankruptcy Court entered an order confirming the Plan (the “Confirmation Order”). On May 9, 2016, the Bankruptcy Court entered an order (the “Order”) approving the Settlement Stipulation entered into between (i) Gregory Rea, RTAT LLC, Nancy Retzlaff, Armistice Capital Master Fund, Ltd. Andrew Pizzo and Sabine Gritti and (ii) the Company (the “Settlement Stipulation”). The Settlement Stipulation provides for the resolution among the parties of a lawsuit filed on January 7, 2016 (the “PIPE Litigation”) in connection with the purchase and sale of the Company’s common stock in the Private Placement, certain objections related to the Company’s bankruptcy proceedings and all related matters. Pursuant to the terms of the Settlement Stipulation, the plaintiffs in the PIPE Litigation received 327,608 shares of the common stock of the Company as reorganized pursuant to the Plan, in addition to certain other consideration.
On the Effective Date, the Plan became effective and the Company emerged from its Chapter 11 bankruptcy proceedings.
On the Effective Date, in accordance with the terms of the Plan, in addition to shares issued to the Lenders and the Purchasers under the Credit Agreement and SPA, respectively, and shares issued in connection with the Settlement Stipulation, the Company reserved for issuance 300,000 shares to the plaintiffs in a class action lawsuit related to the events surrounding the Company’s former Chairman and Chief Executive Officer, and the Company became obligated to issue 3,750 shares to Marek Biestek, a former director, in satisfaction of claims by Mr. Biestek against the Company. In addition, on the Effective Date, the Company reserved for issuance shares of common stock in connection with certain other claims and interests as set forth in the Plan in an amount as yet to be determined.
In accordance with the Plan, on the Effective Date, the Company became obligated to issue promissory notes (the “Notes”) in the estimated aggregate principal amount of approximately $1.3 million to certain holders of allowed general unsecured claims in the Company’s bankruptcy proceedings. The Notes are unsecured, bear interest at a rate of 10% per annum and mature on June 30, 2019.
Savant Arrangements
On February 29, 2016, the Company entered into a binding letter of intent (the “LOI”) with Savant Neglected Diseases, LLC (“Savant”). The LOI provided that the Company would acquire certain worldwide rights relating to benznidazole (the “Compound”) from Savant. Under the LOI, the Company made a non-refundable deposit to Savant of $500,000, which was credited towards the Initial Payment (as defined below), and agreed to make monthly payments to Savant equal to $87,500 for development services performed by Savant relating to the Compound.
The LOI provided that in consideration for the assets to be acquired, the Company would provide consideration to Savant, including:
On the Effective Date, as authorized by the Plan and the Confirmation Order, the Company and Savant entered into an Agreement for the Manufacture, Development and Commercialization of Benznidazole for Human Use (the “MDC Agreement”), pursuant to which the Company acquired certain worldwide rights relating to benznidazole (the “Compound”). The MDC Agreement consummates the transactions contemplated by the LOI.
Under the terms of the MDC Agreement, the Company acquired certain regulatory and non-intellectual property assets relating to the Compound and any product containing the Compound and an exclusive license of certain intellectual property assets related to the Compound. Savant will retain the right to use the licensed intellectual property for veterinary uses. The MDC Agreement provides that the Company and Savant will jointly conduct research and development activities with respect to the Compound, while the Company will be solely responsible for commercializing the Compound. The Company will fund the development program for the Compound and will reimburse Savant for its development program costs.
As required by the MDC Agreement, on the Effective Date, the Company made payments to Savant totaling $2,687,500, consisting of the remaining portion of the Initial Payment less the deposit in the amount of $2,500,000, an initial monthly Joint Development Program Cost payment of $87,500, and reimbursement of Savant’s legal fees capped at $100,000. The MDC Agreement provides for regulatory and other milestone payments of up to $21 million and certain other contingent payments. Additionally, the Company will pay Savant royalties on any net sales of the Compound, which royalty would increase if a PRV is granted subsequent to regulatory approval of the Compound. The MDC Agreement also provides that Savant is entitled to a portion of the amount the Company receives upon the sale, if any, of a PRV regarding the Compound.
In addition, on the Effective Date the Company and Savant also entered into a Security Agreement (the “Security Agreement”), pursuant to which the Company granted Savant a continuing senior security interest in the assets and rights acquired by the Company pursuant to the MDC Agreement and certain future assets developed from those acquired assets.
On the Effective Date, the Company issued to Savant a five year warrant (the “Warrant”) to purchase 200,000 shares of the Company’s Common Stock, at an exercise price of $2.25 per share, subject to adjustment. The Warrant is exercisable for 25% of the shares immediately and exercisable for the remaining shares upon reaching certain milestones related to regulatory approval of the Compound. In addition, pursuant to the MDC Agreement, the Company has granted Savant certain “piggyback” registration rights for the shares issuable under the Warrant.
Governance Arrangements
On the Effective Date, the Company and Martin Shkreli, the Company’s former chief executive officer, former chairman and former controlling stockholder, entered into a Corporate Governance Agreement (the “Governance Agreement”), which provides for certain terms and conditions regarding the acquisition, disposition, holding and voting of securities of the Company by Mr. Shkreli. The Governance Agreement applies to all common stock owned by Mr. Shkreli or affiliates he controls.
Under the terms of the Governance Agreement, for 180 days following the Effective Date, Mr. Shkreli could not sell his shares of common stock at a price per share that was less than the greater of (x) $2.50 and (y) a 10% discount to the prior two week volume-weighted average price (the “Market Discount Price”). In addition, for 180 days following the 61st day after the Effective Date, the Company had a right to purchase any or all of Mr. Shkreli’s shares at a purchase price per share equal to the Market Discount Price. For a limited time, the Company also had a right of first refusal to purchase shares that Mr. Shkreli proposed to sell. Mr. Shkreli was also prohibited from transferring any shares to his affiliates or associates unless such transferee agreed to be subject to the terms of the Governance Agreement. Transfers of shares by Mr. Shkreli not made in compliance with the Governance Agreement would be null and void.
Under the terms of the Governance Agreement, Mr. Shkreli will not have any right to nominate directors to the board of directors of the Company and agreed in connection with any stockholder vote to vote his shares in proportion to the votes of the Company’s public stockholders. The Governance Agreement also prohibits Mr. Shkreli or his affiliates for a period of 24 months after the date of the Governance Agreement, from, among other things:
In addition, any material transaction between Mr. Shkreli or his associates and the Company, or relating to the Governance Agreement, cannot be taken without the prior approval of the Company’s Board.
The Governance Agreement provides for a mutual release between the Company and Mr. Shkreli of all claims and liabilities existing as of the date of execution.
On August 25 and August 26, 2016, Mr. Shkreli sold all of his shares of the Company to third party investors in private transactions.
Stock Issuance
On May 24, 2016, the board of directors approved a one-time equity award (the “Equity Award”) to each of Cameron Durrant, Ronald Barliant and David Moradi. On the Effective Date, in accordance with the Plan, the Company became obligated to issue an aggregate 323,155 shares of common stock under the Equity Award.
Board Changes
On the Effective Date, in accordance with the Plan, Cameron Durrant, current Chief Executive Officer of the Company, as joint designee of BHCMF, BHC and Cheval (the "Black Horse Entities") and Nomis, continued as a director, Ronald Barliant, current member of the Board, continued as a director as the designee of the Black Horse Entities, Dale Chappell became a director as a designee of Nomis, and Timothy Morris and Ezra Friedberg became directors as joint designees of the Black Horse Entities and Nomis. |
Potentially Dilutive Securities (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | ||||||||||||||||||||||||||||||||||||
Potentially Dilutive Securities Tables | ||||||||||||||||||||||||||||||||||||
Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Common Share |
|
Investments (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments, Debt and Equity Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of amortized cost and fair value of investments, with gross unrealized gains and losses | At September 30, 2015, the amortized cost and fair value of investments, with gross unrealized gains and losses, were as follows:
At December 31, 2014, the amortized cost and fair value of investments, with gross unrealized gains and losses, were as follows:
|
Fair Value of Financial Instruments (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of fair value of financial assets and liabilities measured at fair value and classification by level of input |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of changes in financial instruments measured at fair value using Level 3 inputs |
|
Stockholders' Equity (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of stock option activity |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of fair value assumptions |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of total stock-based compensation expense recognized |
|
Restructuring Charges (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of activity in accrued restructuring balance, included within accrued compensation |
|
Nature of Operations (Details) $ in Thousands |
9 Months Ended | |
---|---|---|
Sep. 30, 2015
USD ($)
item
|
Dec. 31, 2014
USD ($)
|
|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Accumulated deficit | $ 200,475 | $ 178,213 |
Liabilities | $ 12,603 | $ 18,364 |
Number of product candidates approved for sale | item | 0 |
Fair Value of Financial Instruments (Details 2) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2015 |
Jun. 30, 2015 |
Mar. 31, 2015 |
Sep. 30, 2015 |
|
Changes in financial instruments measured at fair value using Level 3 inputs | ||||
Beginning balance | $ 227 | $ 92 | $ 89 | $ 89 |
Loss on remeasurement of the financing derivative liability | 114 | 135 | 3 | 252 |
Ending balance | $ 341 | $ 227 | $ 92 | $ 341 |
Notes Payable (Details) - USD ($) |
1 Months Ended | 3 Months Ended | |||
---|---|---|---|---|---|
Nov. 30, 2015 |
Dec. 31, 2015 |
Sep. 30, 2015 |
Aug. 31, 2015 |
Dec. 31, 2014 |
|
Debt Instrument [Line Items] | |||||
Restricted cash, short-term | $ 7,802,000 | ||||
Loan And Security Agreement [Member] | |||||
Debt Instrument [Line Items] | |||||
Carrying value of notes payable | $ 8,425,000 | $ 8,300,000 | |||
Restricted cash, short-term | $ 7,800,000 | ||||
Loan And Security Agreement [Member] | Subsequent Event [Member] | |||||
Debt Instrument [Line Items] | |||||
Repayments of debt | $ 6,600,000 | ||||
Prepayment fee (as a percent) | 1.00% | ||||
Gain on extinguishment of debt | $ 61,000 |
Commitments and Contingencies (Details) |
9 Months Ended |
---|---|
Sep. 30, 2015
USD ($)
| |
Commitments and Contingencies Disclosure [Abstract] | |
Accruals or expenses related to indemnification issues |
Stockholders' Equity (Black-Scholes Weighted-Average Assumptions) (Details) - $ / shares |
3 Months Ended | 9 Months Ended |
---|---|---|
Sep. 30, 2015 |
Sep. 30, 2015 |
|
Stockholders Equity Black-scholes Weighted-average Assumptions Details | ||
Exercise price | $ 3.23 | $ 3.59 |
Market value | $ 3.23 | $ 3.59 |
Risk-free rate | 1.62% | 1.61% |
Expected term | 5 years 3 months 18 days | 5 years 9 months 22 days |
Expected volatility | 69.00% | 70.00% |
Dividend yield |
Stockholders' Equity (Reverse Stock Split) (Details) |
9 Months Ended | ||
---|---|---|---|
Sep. 30, 2015
shares
|
Jul. 13, 2015
shares
|
Dec. 31, 2014
shares
|
|
Reverse stock split ratio | 8 | ||
Shares oustanding | 4,123,921 | 4,100,000 | 4,124,004 |
Scenario, Previously Reported [Member] | |||
Shares oustanding | 33,000,000 |
!QN'V3]I=4O
M4$L#!!0 ( .*%(4E.!KO_H $ +$# 8 >&PO=V]R:W-H965T.>%6N\]%VF6YNP&UL?5/;
M;MP@$/T5Q <$+^OM9>6UE$U4M0^5HCRTSZP]ME& <0"OT[\O8*_CME9?@!GF
MG#DS#,6(]L5U )Z\:67
0O/Z"=DY[KA
MWH$*.8;TL#A1*I!,,7B2-:_D^S,<,#H)M5W(/3,CV1P$;6\/S/#*%?\ 4$L#
M!!0 ( .*%(4FA*G6D9 ( (T( 9 >&PO=V]R:W-H965T7(>\;9"7M'U
MWG6]7C/DT# EA "11]8PR**Z;.L5-!-Q(T0=+0.VCFM'8ZS)CWFF?7!W/X1@
M)-M%;L@]E*]OMQAG>9/D(K-B1SW0$O4*W0VP*2T6K/'B: _=YLNP'X56 69G
M-2_3M1X5N'?TK*[27(&,_D.2%<_2HNI= 3*ODKFJR<*"DP6Z[D>'^/"__=/_
M%4_CO_W3OP+G D1S=)B[;U!0A0>@8.;$WZC]&).,@[8W(P.!J*/ Y%#2T5#U2?
M< 6*CE&L42@FG^!<0"5=$250F!%I2R)C3&R@ZLZ9S)(5T[N6TA9_<)5V!X\!
M-LWIGAD!![3V^:9V$([5M$6*>K>KK0D5%)6S#]\\,HZ+/]>+&]IXBG"Z*[([
M7O%"H
M
8AV4PY!W2S"+;;JJ5[, _*1?'IKNR[TTB
M_Z]M-"10I/ QYM"SMH+V85GG]U3R97/H$T0"/SY3F,YB$?$YA3WCDXS" -2B
MW:U^0)7$%J0:OG!140J+53N;Z]TO::ZT)I!)E=N6S?MWE3G7LF\U-,ALW!3%
M)SV$3AXE!8\)R313E@;CTOJ36,+PU$V?T(V6*:_A9/#]5NU15XZY:7QE4"5'
MM=0SX0_(O2:U4?#M):>EQG!.6MV^-)AY14GS%(.